AstraZeneca PLC
Close on Oct 19, 2026Market cap $255.76BP/E 25.1Yield 1.91%
AstraZeneca Enhertu (trastuzumab deruxtecan by Quarter
Enhertu (trastuzumab deruxtecan — direct product sales) — Worldwide YoY CER (%) (%)
AstraZeneca Enhertu (trastuzumab deruxtecan: 44.0% in Q2 2026, down 38.0 pts from a year earlier. That is the lowest of the 8 quarters on record here.
Where the Q2 2026 figure comes from
“|| Enhertu | | 338 | | 47 | | 44 | | - | | - | | 223 | | 43 | | 41 | | 68 | | 34 | | 28 | | 47 | | n/m | | 98”
Source: Form 6-K FY2026Q2 Earnings Release ↗
Reported in Form 6-K / 20-F Product Sales Table.
Quarterly history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Enhertu (trastuzumab deruxtecan — direct product sales) — Worldwide YoY CER (%) (%) | Year on year | Source |
|---|---|---|---|---|
| Q2 2026 | Jun 30, 2026 | 44.0% | -38.0 pts | Form 6-K FY2026Q2 Earnings Release ↗ |
| Q1 2026 | Mar 31, 2026 | 56.0% | -15.0 pts | Form 6-K FY2026Q1 Earnings Release ↗ |
| Q4 2025 | Dec 31, 2025 | 95.0% | -3.0 pts | Form 6-K FY2025Q4 Earnings Release ↗ |
| Q3 2025 | Sep 30, 2025 | 75.0% | – | Form 6-K FY2025Q3 Earnings Release ↗ |
| Q2 2025 | Jun 30, 2025 | 82.0% | -17.0 pts | Form 6-K FY2025Q2 Earnings Release ↗ |
| Q1 2025 | Mar 31, 2025 | 71.0% | – | Form 6-K FY2025Q1 Earnings Release ↗ |
| Q4 2024 | Dec 31, 2024 | 98.0% | – | Form 6-K FY2024Q4 Earnings Release ↗ |
| Q2 2024 | Jun 30, 2024 | 99.0% | – | Form 6-K FY2024Q2 Earnings Release ↗ |
Cite this data
StockData. (2026). AstraZeneca Enhertu (trastuzumab deruxtecan (%), quarterly Q2 2024–Q2 2026 [Data set]. Compiled from AstraZeneca SEC filings and investor materials. https://stockdatahq.com/stocks/azn/kpis/med-enhertu-world-cer-yoy
See every metric in the AstraZeneca KPI table. Data updated Oct 28, 2026.